Abstract-Screening of an expression human liver cDNA library resulted in the isolation of several cDNA clones homologous to sterol regulatory element-binding protein-1 (SREBP-1) that recognize the regulatory element AIIAB and AIIK of the human apoA-II promoter. DNaseI footprinting of the apoA-II promoter using SREBP-1 (1 to 460) expressed in bacteria identified 5 overall protected regions designated AIIAB (Ϫ64 to Ϫ48), AIICD (Ϫ178 to Ϫ154), AIIDE (Ϫ352 to Ϫ332), AIIHI (Ϫ594 to Ϫ574), and AIIK (Ϫ760 to Ϫ743). Key Words: sterol regulatory element-binding protein-1 Ⅲ apoA-II Ⅲ transcriptional regulation Ⅲ basic helix-loop-helix zipper factors Ⅲ upstream regulatory factor S terol regulatory element-binding protein 1 (SREBP-1) was initially identified as the transcription factor that recognizes the sterol regulatory element-1 (SRE-1) of the LDL receptor promoter. 1,2 Two isoforms of SREBP-1, 1a and 1c, have been described along with a homologous protein designated SREBP-2. 3,4 Although SREBP-1 and SREBP-2 belong to the family of basic helix-loop-helix zipper (bHLHZip) proteins, they are much larger than other bHLHZip proteins, having 1147 and 1141 amino acids, respectively, and can recognize direct (CACCCCAC) as well as E-box type (CANNTG) palindromic repeats. 3-5 SREBP family members possess 2 transmembrane domains that anchor them to the endoplasmic reticulum. 6 -8 Their transcriptional activation domain is highly acidic and is located at the amino terminus. 7 On sterol depletion, the protein is cleaved by 2 proteases to produce the active part of the molecule of molecular weight (M r ) 68 kDa that translocates to the nucleus and activates the cholesterol-responsive genes. 6,8 -10 The SREBP-1 protein was also cloned independently by screening of an adipocyte expression library with E-box elements as probes. 11 The protein was named ADD1 for adipocyte differentiation-dependent protein 1 on the basis of its induction after differentiation of the 3T3L1 preadipocytes. It has been proposed, on the basis of the high levels of expression of SREBP-1 in liver and fat tissues, that SREBP family members may regulate not only cholesterol-responsive genes 1,2 but also genes involved in fatty acid biosynthesis and metabolism in adipocytes. [12] [13] [14] [15] After the cloning of SREBP-1 and SREBP-2, other genes have been shown to be regulated by the same factors. Many of them are involved in cholesterol and fatty acid metabolism. 9, [13] [14] [15] 
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terol regulatory element-binding protein 1 (SREBP-1) was initially identified as the transcription factor that recognizes the sterol regulatory element-1 (SRE-1) of the LDL receptor promoter. 1, 2 Two isoforms of SREBP-1, 1a and 1c, have been described along with a homologous protein designated SREBP-2. 3, 4 Although SREBP-1 and SREBP-2 belong to the family of basic helix-loop-helix zipper (bHLHZip) proteins, they are much larger than other bHLHZip proteins, having 1147 and 1141 amino acids, respectively, and can recognize direct (CACCCCAC) as well as E-box type (CANNTG) palindromic repeats. [3] [4] [5] SREBP family members possess 2 transmembrane domains that anchor them to the endoplasmic reticulum. 6 -8 Their transcriptional activation domain is highly acidic and is located at the amino terminus. 7 On sterol depletion, the protein is cleaved by 2 proteases to produce the active part of the molecule of molecular weight (M r ) 68 kDa that translocates to the nucleus and activates the cholesterol-responsive genes. 6,8 -10 The SREBP-1 protein was also cloned independently by screening of an adipocyte expression library with E-box elements as probes. 11 The protein was named ADD1 for adipocyte differentiation-dependent protein 1 on the basis of its induction after differentiation of the 3T3L1 preadipocytes. It has been proposed, on the basis of the high levels of expression of SREBP-1 in liver and fat tissues, that SREBP family members may regulate not only cholesterol-responsive genes 1,2 but also genes involved in fatty acid biosynthesis and metabolism in adipocytes. [12] [13] [14] [15] After the cloning of SREBP-1 and SREBP-2, other genes have been shown to be regulated by the same factors. Many of them are involved in cholesterol and fatty acid metabolism. 9, [13] [14] [15] Analysis of sterol-resistant Chinese hamster ovary (CHO) cell lines have provided strong evidence for the physiological significance of SREBPs in the negative-feedback loop that regulates the expression of the LDL receptor. These cell lines have a frameshift mutation that produces a truncated SREBP-2 protein lacking the transmembrane domain. 16 This truncated SREBP-2 form constitutively activates the LDL receptor and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) synthase genes.
Human apoA-II is a major protein component of HDL and is synthesized by the liver and to a much lesser extent by the intestine. 17, 18 Genetic studies in mice have pointed out that apoA-II may alter the antiatherogenic functions of apoA-I and may thus contribute to the pathogenesis of atherosclerosis. 19, 20 The transcription of the human apoA-II gene is controlled by a complex array of distal and proximal regulatory elements, designated AIIA to AIIN, which have been divided in 3 functional regions. The distal region (Ϫ911/ Ϫ614) consists of elements AII-I to AIIN and displays an enhancer-type activity with heterologous promoters in HepG2 cells. 21, 22 Important for the overall promoter activity is also the regulatory element AIIAB located in the proximal region.
Recently, we have also characterized several previously described as well as new transcription factors that bind to these elements. 21 An important regulatory role is exerted by the factor CIIIB1 23 that binds to the regulatory elements AIIAB, AIIK, and AIIL. Simultaneous nucleotide substitutions that prevented the binding of CIIIB1 to elements AIIAB, AIIK, and AIIL reduced the hepatic and intestinal transcription to 6% to 7% of control. 24 , 25 The current study shows that SREBP-1 binds to previously described as well as new regulatory elements and transactivates the human apoA-II promoter. Two of the binding sites of SREBP-1 on elements AIIAB and AIIK overlap with the binding site of CIIIB1, which was shown recently to correspond to the bHLHZip upstream stimulatory factor (USF). 26 In addition, use of SREBP-1 mutants defective in DNA binding or transcriptional activation has provided new insights in the activation of the apoA-II promoter by SREBP-1.
Methods

Materials
The Klenow fragment of the DNA polymerase I, restriction enzymes, T 4 ligase, T 4 polynucleotide kinase, and Vent polymerase were purchased from New England Biolabs. [␥ 32 P]ATP (5000 Ci/mmol), [␣ 32 P]dCTP, and [␣ 32 P]dGTP (3000 Ci/mmol) were purchased from New England Nuclear. DNaseI was from Worthington. Anti-FLAG monoclonal antibody was from Kodak, IBI. The secondary antibody was from Santa Cruz. O-nitrophenyl-1 D-galacto-␤-pyranoside (ONPG), cholesterol, and 25-OH-cholesterol were from Sigma. Chloramphenicol acetyltransferase (CAT) ELISA kit was from Boehringer Mannheim. The RNase protection kit and the ␤-actin probe were purchased from Ambion. Sequenase 2.0 and the ECL system were from Amersham. Reagents for automated DNA synthesis were purchased from Applied Biosystems, Inc. Bactotryptone and bacto yeast extract were purchased from Difco. Double-stranded poly(dI-dC) was purchased from Pharmacia LKB Biotechnology, Inc. Acrylamide, SDS, urea, and Tris were purchased from International Biotechnologies, Inc. Bacterial XL-1 Blue cells were purchased from Stratagene.
Preparation of Concatenated Probes and Screening of Human Liver cDNA Library
Ten micrograms each of the sense and the antisense strands of a single-stranded oligonucleotide of AIIAB having 3 G or C, respectively, at their 5Ј and 3Ј ends (Table 1) were phosphorylated for 2 hours at 37°C using T 4 polynucleotide kinase. Ten micrograms each of the sense and antisense strands of the single-stranded oligonucle- The underlining shows location of the restriction sites introduced by PCR. The sites of the mutations are italic.
otides AIIAB (Table 1) were annealed and purified by phenol extraction and ethanol precipitation. The annealed oligonucleotides were ligated with T 4 DNA ligase to produce concatenated probes that were labeled by nick translation. Plating and screening of the human liver cDNA library was performed as described. 27 Briefly, the pellet from 20 mL of overnight culture of Escherichia coli (Y1090(r Ϫ )) was dissolved in 8 mL of ice-cold 10 mmol/L MgSO 4 , and cells from 0.2 mL of the overnight culture were infected with 0.1 mL of 1ϫ dilution buffer containing 10 000 plaque-forming units (pfu) of gt11, human liver cDNA library, Clontech. They were incubated at 37°C for 15 minutes, mixed with 6 mL of top agarose (45°C), and plated on 150-mm-diameter prewarmed plates (42°C). After 3 to 4 hours' growth at 42°C, the plates were covered with dried filters that had been soaked in 10 mmol/L isopropyl-␤-D-galactopyranoside (IPTG) and incubated overnight at 37°C. The next day, the filters were lifted and air-dried. Proteins bound to the filters were denatured by treatment with denaturing solution containing 5 mol/L guanidine hydrochloride (GnHCl) and renatured by sequential dilution of the solution followed by 5 minutes' incubation of the filters at 4°C. Next the filters were incubated in blocking solution (Blotto) containing 5% nonfat dry milk and were washed with washing solution (20 mmol/L HEPES, pH 7.6, 50 mmol/L KCl, 5 mmol/L MgCl 2 , 1 mmol/L EDTA, 0.25% nonfat dry milk, 8% glycerol, 1 mmol/L DTT, pH 7.6, 0.1% Triton X-100) to remove excess milk. Hybridization solution was added and the filters were hybridized overnight at 4°C. The filters were washed the following day for 10 minutes, air-dried, and autoradiographed as described. 27 Candidate clones underwent secondary and tertiary screening to isolate pure clones.
To isolate DNA from pure phage clones, Y1090(r Ϫ ) cells were infected with phage particles at a multiplicity of infection of 8:1 to ensure confluent lysis and were plated on a 150 mmol/L plate (Luria broth-agarose). After 4 to 5 hours at 42°C, the cell lysate was extracted in 10 mL of sodium magnesium buffer (0.1 mol/L NaCl, 0.01 mol/L MgSO 4 , 0.05 mol/L Tris-Cl pH 7.5 and 2% gelatin) by incubation at 4°C overnight. The SM buffer was transferred to a 15-mL tube and centrifuged for 10 minutes at 6000 rpm at 4°C to remove debris. The supernatant was transferred to a clean tube and centrifuged for 90 minutes at 25 000 rpm at 4°C using an SW41 rotor (Beckman Co). The pellet was resuspended in 400 L of deionized H 2 O, 50 L of 10% SDS, 40 L of 0.5 mol/L EDTA, and 25 L of proteinase K (20 mg/mL), and the mixture was incubated at 65°C for 10 minutes. The DNA was then purified by chloroform extraction and ethanol precipitation, and stored at Ϫ80°C. The DNA was digested with EcoRI, and the insert was subcloned into pBluescript SK vector (Stratagene). Partial DNA sequence was obtained from both ends using the Sequenase 2.0 kit (Amersham). The sequences obtained were submitted for homology comparison against the sequences deposited in Genbank.
Plasmid Constructions
ApoA-II Promoter Mutants
To remove the middle elements AIIC to AIIF from the apoA-II promoter, the Ϫ911 to Ϫ616 and Ϫ67 to 29 regions were amplified separately by PCR using the Ϫ911/29 apoA-II pUCSH CAT plasmid as a template. 25 The region of the apoA-II enhancer (Ϫ911 to Ϫ616) was amplified with the 5-rev-26 and AII3ApaI primers ( Table 1) . The proximal region of the apoA-II promoter was amplified with the primers AIIAB and 3-CAT-26. The primers AII3ApaI and AIIAB contain an ApaI site. The PCR products were digested with XbaI and ApaI (Ϫ911 to Ϫ616) and with ApaI and XhoI (Ϫ67 to 29). The parental pUCSH CAT vector 23 was also digested with XbaI and XhoI. The 2 PCR fragments and the pUCSH CAT vector were ligated in a triple ligation to produce apoA-II promoter with deletion of the region Ϫ616 to Ϫ67 (AIIAB wild-type AIIK wild-type). The mutation of the AIIK element was produced by amplification of the apoA-II enhancer with 2 sets of overlapping primers (5-rev-26 and AIIK3) and (AIIK4 and AII3ApaI). An aliquot containing 1% of each of the PCR products was mixed and amplified with the external 5-rev-26 and AII3ApaI primers. The mutant enhancer was digested with XbaI and ApaI. The AIIAB element was mutated by amplification of the wild-type apoA-II promoter with the primers AIIABM7 and 3-CAT-26. The PCR product was digested with ApaI and XhoI.
The mutant apoA-II enhancer was ligated to the wild-type proximal (Ϫ67 to 29) region and the pUCSH CAT vector to produce the AIIAB wild-type AIIK mutant construct. Alternatively the mutant apoA-II enhancer was ligated to the mutated Ϫ67 to 29 region and the pUCSH CAT vector to produce the AIIAB mutant AIIK mutant construct. Finally, the wild-type apoA-II enhancer was ligated to the mutated Ϫ67 to 29 region and the pUCSH CAT vector to produce the AIIAB mutant AIIK wild-type construct. The final constructs and the mutations in the elements AIIAB and/or AIIK were verified by DNA sequencing.
Wild-type and Mutant SREBP-1 Expression Plasmids
The cDNA for the SREBP-1a was kindly provided by Dr M. Brown (University of Texas Health Science Center). 4 The flagged versions of SREBP-1 (1-460) were constructed by PCR-mediated ligation. Briefly, 2 regions of SREBP-1 cDNA (Ϫ132 to 1 and 1 to 1548) were amplified separately with 2 sets of primers (SREBP-1A, SREFLAGR) and (SREFLAGF, SREBP-1R) ( Table 1 ). The primers SREFLAGF and SREFLAGR contained overlapping portions of the FLAG peptide sequence (DYKDDDDK). In the next PCR, an aliquot containing 2% of the 2 amplification products were mixed together and amplified with the outside primers (SREBP-1A and SREBP-1R; Table 1 ) to produce the final product. These 2 primers contained restriction sites for the BamHI and EcoRI enzymes that were used to subclone the construct into the corresponding sites of the pcDNAI-.Amp vector (Invitrogen). The final protein contains the FLAG peptide followed by 460 amino acids of SREBP-1. The SREBP-1 deletion mutant was constructed using the same strategy but different sets of overlapping primers (SRE90FLG and SREFLAGR). Both primers contain the overlapping FLAG sequence; however, the SRE90 FLAG corresponds to the cDNA region encoding amino acids 90 to 94 (Table 1) . For the construction of the point mutants in the DNA-binding domain of SREBP-1, 2 overlapping oligonucleotides were used that contained 2 degenerate bases corresponding to the amino acid Lys359 (SREKI-F2 and SREKI-R2). After DNA amplification, this degeneracy resulted in the production of 4 different mutated cDNAs that had the Lys359 mutated to Arg, Val, Gly, or Ile. All the mutant cDNA were confirmed by restriction enzyme digestion and DNA sequencing of the mutated regions.
Expression of SREBP-1 Protein in BL21(DE3) Cells
The region 167 to 1548 of the SREBP-1 cDNA, which encodes a protein of 460 amino acids, was amplified and subcloned into the NdeI and EcoRI sites of the bacterial vector pAED4 (pET3a derivative). The construct was used to transform E coli BL21 (DE3). This strain expresses T7 RNA polymerase under the control of lac promoter. An overnight culture of bacteria was diluted 80-fold in 4 mL of Luria broth medium containing 100 g/mL ampicillin and incubated for approximately 1.5 hours. Isopropyl-␤-Dthiogalactopyranoside (IPTG) was then added to a final concentration of 1 mmol/L, and the culture was maintained for an additional 3 hours. Next the bacteria were spun for 5 minutes at 5000 rpm, and the pellet was dissolved in 0.5 mL of denaturation buffer (20 mmol/L HEPES, pH 7.6, 50 mmol/L KCl, 5 mmol/L MgCl 2 ,1 mmol/L EDTA, 8% glycerol, 1 mmol/L DTT, 6 mol/L GnHCl, pH 7.6) supplemented with protease inhibitors (1 mmol/L aprotinin, 1 mmol/L benzamidine, 1 mmol/L leupeptin, 1 mmol/L PMSF). The bacterial lysates were rotated on a platform for 30 minutes at 4°C and centrifuged for 5 minutes in a microfuge, and the supernatant was dialyzed twice for 1 hour against an excess of the denaturation buffer without GnHCl and containing 1 mmol/L PMSF. After dialysis, the extracts were centrifuged for 5 minutes at 4°C in a microfuge to remove precipitated material, and the supernatant containing SREBP-1 was stored at Ϫ80°C.
DNaseI Footprinting Assays
The Ϫ911/29, Ϫ614/29, and Ϫ440/29 apoA-II pUCSH CAT constructs 25 were amplified with external primers (5-rev-26 and 3-CAT-26; Table 1 ). The primer 5-rev-26 was end-labeled with T 4 polynucleotide kinase. These PCR products were used to footprint the distal (AIIK, AIIHI, and AIIDE) SREBP-1-binding sites. To footprint the proximal (AIIAB and AIICD) sites, the Ϫ911/29 apoA-II pUCSH CAT 25 was digested with XhoI, end-labeled with T 4 polynucleotide kinase, and then digested with SalI. To footprint SREBP sites on the apoC-III promoter, the Ϫ890/24 apoC-III pUCSH CAT 23 was digested with XhoI, end-labeled with T 4 polynucleotide kinase, and then digested with XbaI. All the labeled promoter fragments were separated on 5% polyacrylamide gel electrophoresis (PAGE) and purified by electroelution. Footprinting was performed with 4-L extracts of bacteria expressing SREBP-1 as described. 23 The position of the binding sites of SREBP-1 in the apoA-II and apoC-III promoters were determined by comparing the SREBP-1 footprints with the GϩA ladder produced by chemical cleavage of the same DNA fragment.
Gel Electrophoretic Mobility Shift Assays
This analysis was performed with 1-L extracts of bacteria expressing SREBP-1 as described. 23 The final probe concentration in all reactions was 2.5 nmol/L (50 000 cpm). The competitors were used at 10-to 250-fold excess in relation to the 32 P labeled probe.
Transient Transfection Assays
Human hepatoma HepG2 cells and monkey kidney COS-1 cells were routinely grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% FBS. HepG2 cells were plated in 30-mm dishes at a density of 5ϫ10 5 /plate in DMEM supplemented with 10% FBS. They were transfected by calcium phosphate coprecipitation method with a total of 6 g of DNA (3 g of reporter CAT plasmid, 1 g of cytomegalovirus (CMV) ␤-galactosidase (␤-gal), and appropriate amounts [0.2 to 2 g] of SREBP-1). COS-1 cells were transfected with 4 g of hepatic nuclear factor 4 (HNF-4) or the FLAG-SREBP-1 (1-460) and used for the production of whole cell extracts. Forty-eight hours after transfection, cells were lysed with lysis buffer (Boehringer Mannheim) for 30 minutes at room temperature. The lysates were collected and used for CAT and ␤-gal assays. All experiments were done in duplicate and repeated at least 3 times.
The relative amounts of the CAT enzyme in the cells was determined by sandwich ELISA assays using the CAT ELISA kit (Boehringer Mannheim). The method uses 96-well plates coated with anti-CAT antibody. 28 The lysate was added for 1 hour and incubated at 37°C. After 5 washes with the wash solution, anti-CAT antibody labeled with digoxigenin was added to the wells, and the mixture was incubated for an additional hour. The antibody was then removed by 5 washes, and the secondary antibody conjugated with horseradish peroxidase was added for 1 hour. After the incubation, the samples were washed 5 times and the 2,2Ј-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) diammonium salt (ABTS) substrate was added to the wells. The absorbance of the solution was then measured at 410 nm. 28 The ␤-gal activity of the extracts was used to normalize the efficiency of transfection.
SDS-PAGE and Western Blotting Analysis
Protein extracts were analyzed on standard (10% resolving, 4% stacking) mini Protean gels (Bio-Rad) in Tris glycine buffer (0.025 mmol/L Tris, 0.2 mol/L glycine, 0.1% SDS). After electrophoresis, the proteins were either stained with Coomassie brilliant blue for direct visualization or transferred to nitrocellulose filters for 1 hour at 100 V in transfer buffer (0.025 mmol/L Tris, 0.2 mol/L glycine, 20% methanol). The bound proteins, carrying the FLAG epitope at the amino terminus (DYKDDDDK), were detected using monoclonal anti-FLAG M2 antibody (Kodak, IBI). Briefly, the membranes were blocked with 5% nonfat dried milk in 50 mmol/L Tris HCl, pH 7.4, and 150 mmol/L NaCl for 30 minutes at room temperature. The primary antibody was then added to a final concentration of 10 g/mL for 30 minutes. After the incubation, the membranes were washed briefly twice with the same solution without milk. The secondary antibody conjugated with horseradish peroxidase (HRP) (Santa Cruz) was added in dilution 1:1000 in blocking solution, and the membranes were incubated for 30 minutes. Before detection, the membranes were washed 3 times in the same solution without milk for 5 minutes each time, and the proteins were detected with the enhanced chemiluminescence (ECL) system (Amersham).
Results
Human ApoA-II Promoter Contains 5 Binding Sites for SREBP-1
Screening of 10 6 plaques of a human liver cDNA library (Clontech) for transcription factors that recognize the regulatory element AIIAB of the human apoA-II promoter resulted in the isolation of 4 cDNA clones homologous to SREBP-1. Limited sequencing of the 4 clones showed identity with the 447 to 546, 545 to 609, 819 to 848, and 2565 to 2624 nucleotide sequences of SREBP-1 on the basis of the Genbank sequence information. 4 The existence of an SREBP-1-binding site on the human apoA-II promoter prompted us to investigate further the role of SREBP-1 on the transcriptional regulation of the human apoA-II gene. It was shown previously that the amino terminal segment of SREBP-1, extending to amino acids 410, 476, or 513, translocates directly into the nucleus. 7 This bypasses the requirement for sterol-regulated proteolytic cleavage of the intact SREBP-1 molecule to generate the transcriptionally active amino-terminal form. 8 Initially a 1.55-kb segment of SREBP-1 cDNA encoding for the first 460 amino acids was expressed in E coli BL21(DE3) strain, and bacterial extracts containing SREBP-1 were prepared. With these bacterial extracts, DNaseI footprinting showed that SREBP-1 binds to 5 distinct sites in the apoA-II promoter. Two of these sites, AIIAB (Ϫ64 to Ϫ48) and AIIK (Ϫ760 to Ϫ743), were previously identified as binding sites for rat liver nuclear proteins. 25 The remaining 3 sites, designated AIICD (Ϫ178 to Ϫ154), AIIDE (Ϫ352 to Ϫ332), and AIIHI (Ϫ594 to Ϫ574), are unique binding sites for SREBP-1 and are located between the previously defined footprints C and D, D and E, and H and I, respectively (Figure 1A through 1D and 1F).
DNaseI footprinting analysis was also performed with the human apoC-III promoter, because the library screening also showed that SREBP-1 recognizes the regulatory element CIIIB (data not shown). This element has been shown to contain a hormone response element (HRE) that binds a variety of nuclear hormone receptors, including HNF-4. 29 HNF-4 expressed in COS-1 cells and SREBP-1 (1-460) expressed in bacterial cells were used for this purpose. This analysis showed that the 2 factors bind to overlapping sites within the CIIIB element ( Figure 1E and 1G) . The binding site of SREBP-1 coincides with the binding site of the factor CIIIB1, which has been previously characterized by us 30 and was shown recently to correspond to the transcription factor USF. 26 
Comparison of the SREBP-1-Binding Sites Found in the ApoA-II and ApoC-III Promoters to Previously Reported SREBP-Binding Sites
Alignment of SREBP-1-binding sites from the apoA-II and apoC-III promoters identified by DNaseI footprinting, previously reported consensus SREBP-binding sites, and the original SRE found on the LDL receptor is shown in Table 2 . The SREBP-1-binding sites on the apoA-II promoter contain either an inverted E-box type palindromic repeat of CANNTG, or a sequence highly homologous to the direct repeat ATCAC-CCCAC. 4 This direct repeat is found in the SRE-1 element of the LDL receptor, which is recognized only by SREBP.
The binding of SREBP-1 to the regulatory elements identified by DNaseI footprinting was also tested by gel electrophoretic mobility shift assays (EMSA). For this purpose, double-stranded oligonucleotides corresponding to the protected regions defined by DNaseI footprinting were synthesized and used as probes in EMSA (Table 3) . Extracts of bacteria transformed with the empty expression vector were used as a negative control. This analysis showed that SREBP-1 expressed in bacteria can bind to all 5 elements of the apoA-II promoter. The binding is competed out by excess of unlabeled oligonucleotide, indicating that the binding is specific. No binding was observed in lanes containing extract from bacteria from cells transformed with the empty vector pAED4 (Figure 2A) .
The relative affinity of the 5 SREBP-1-binding sites on the apoA-II and apoC-III promoters were compared by extensive competition assays using the SRE-1 element from the LDL promoter as a probe and competing with oligonucleotides containing SREBP-1-binding sites from the apoA-II and apoC-III promoters and the original SRE-1 found in the LDL receptor promoter. The concentrations of the competitor oligonucleotides used were 10-to 250-fold molar excess over the probe. Figure  2B shows that the unlabeled SRE-1 and the AIIAB elements of the LDLR and apoA-II promoters, respectively, compete with comparable efficiency for binding to the labeled SRE-1 probe. The order of competition of the probes for the binding of SREBP-1 to the element SRE-1 is approximately SRE-1ϳAIIABϾAIIKϾAIICDϳAIIDEϳAIIHIϾCIIIB.
SREBP-1 (1-460) Transactivates the Human ApoA-II Promoter
The Ϫ911/29 apoA-II region is a strong promoter in cells of hepatic origin, and its activity is approximately 30% of the activity of CMV promoter (H.-Y. Kan and V.I. Zannis, unpublished data, 1997). To evaluate the effect of SREBP-1 on the activity of the human apoA-II promoter, plasmids expressing the amino-terminal portion of SREBP-1 cDNA encoding the amino acids 1 to 460, along with different apoA-II promoter constructs, were used in the cotransfection experiments of HepG2 cells. This analysis showed that SREBP-1 transactivated 3.5-fold the human apoA-II promoter ( Figure 3A) . The transactivation reaches a plateau at Ϸ200 ng of SREBP-1 expression plasmid, suggesting either that saturation of the apoA-II promoter occurs or that another factor may become limiting. This 3.5-fold transactivation is significant given the very strong activity of the apoA-II promoter in HepG2 cells. A mutated (Ϫ614/29) apoA-II promoter, which lacks the apoA-II enhancer region and contains the regulatory elements AII-I to AIIN, has approximately 1% of the activity of the Ϫ911/29 apoA-II promoter in HepG2 cells. 25 This promoter is transactivated 40-fold by 500 ng of SREBP-1 expression plasmid. The activity of this truncated promoter reaches approximately 40% of the wild-type promoter activity in the presence of SREBP-1 ( Figure 3A) .
The truncated apoA-II promoter segments that contain only 1 (AIIϪ80/29), 2 (AIIϪ230/29), 3 (AIIϪ440/29) or 4 (AIIϪ614/29) SREBP-1-binding sites were also tested for transactivation by SREBP-1 ( Figure 3B and 3C) . The transactivation of these truncated apoA-II promoter segments initially increases with the number of SREBP-1-binding sites present and ranges from 10-fold for the AIIϪ80/29 construct, which has 1 SREBP-1-binding site, to approximately 40-fold for the AIIϪ440/29 and AIIϪ614/29 promoter constructs, which have 3 and 4 SREBP-1-binding sites, respectively ( Figure 3B ). These truncated promoter constructs provide a useful set of reporter plasmids to explore further the structure and functions of SREBP-1 family members.
Previous mutagenesis analysis indicated that elements AIIAB and AIIK are very important for promoter activity in HepG2 cells. These elements are also SREBP-1-binding sites. Point mutations or deletions of these elements reduced the promoter activity to 10% to 20% of the control in HepG2 cells. 21, 24 To test the importance of these elements in the SREBP-1-mediated transactivation, 4 new apoA-II promoter constructs were made carrying an internal deletion that removed elements AIIC to AIIH and linked the enhancer region (AII-I to AIIN) to element AIIAB. One construct has both elements intact (AB wild-type K wild-type). Two constructs carry mutations either in element AIIAB (AB mutant K wild-type) or in element AIIK (AB wild-type K mutant), and 1 construct carries mutations in both elements AIIAB and AIIK (AB mutant K mutant). The mutations were designed to eliminate the binding of SREBP-1 to this site and test the contribution of the individual sites in SREBP-1 mediated transactivation as well as possible synergism between SREBP-1 molecules bound to the proximal and the distal site. The same mutations, designed to abolish the binding of SREBP-1, were introduced into elements AIIAB and AIIK, and the mutant oligonucleotides were used as probes or competitors in DNA binding assays (Table 3 ). In agreement with previous findings, 25 transient cotransfection assays using these constructs showed that the internal deletion of the region (Ϫ616 to Ϫ67) does not decrease the apoA-II promoter activity in HepG2 cells, but rather increases the activity of the mutant promoter 2-fold ( Figure 4A and 4B). The introduction of mutations in elements AIIAB and AIIK progressively decreased the activity of the mutant apoA-II promoter constructs. Although the promoter activity of the constructs carrying mutations in elements AIIAB or AIIK was comparable with that of the wild-type promoter, the extent of transactivation was not affected by mutations in element AIIK but was reduced significantly by mutations in element AIIAB ( Figure 4A and 4B) . A small increase in transactivation observed with the construct carrying a double mutation may represent residual weak binding to the mutated site AIIK ( Figure 5 ). The effect of the mutations on DNA binding was tested by DNA binding gel electrophoresis and competition assays. The competition experiments showed that the mutated oligonucleotides (AIIAB mutant, AIIABM1, and AIIK mutant) ( Table 3) have decreased ability to compete for the binding of SREBP-1 to the wild-type oligonucleotides. The direct binding assays demonstrated that the mutations severely affect the ability of SREBP-1 to bind to the mutated elements AIIAB and AIIK ( Figure 5 ).
SREBP-1 Mutants Defective in DNA Binding or Transcriptional Activation Repress the ApoA-II Promoter Activity
Early cotransfection experiments with an SREBP-1 (1-460) form produced by PCR amplification of the SREBP-1 cDNA resulted in a dose-dependent repression of the apoA-II promoter activity. 31 Sequence analysis of this construct revealed that it contained a substitution of Ile for Lys359, introduced during the amplification and cloning of the SREBP-1. Close examination of the position of this amino acid across the members of the family of bHLHZip binding proteins showed that it is located at the beginning of helix 2 of the bHLHZip domain and it is highly conserved among the members of the family ( Figure 6D ). To elucidate the mechanisms of this repression, we introduced additional mutations into the same position, changing the Lys359 to either Gly, Val, or Arg. To monitor the expression of these mutant SREBP-1 (1-460) forms, the flagged version of different SREBP-1 mutants were cloned in mammalian and bacterial vectors. Immunoblot analysis was used to assess their expression after transient Figure 2 . A, Gel EMSA and competition assays using several SREBP-1-binding sites as probes or competitors. DNA binding and competition assays were performed with SREBP-1 (1-460) expressed in bacteria as explained in the Methods. The competitor oligonucleotides were used at 20-or 100-fold molar excess relative to the 32 P labeled probe. The probes and the competitor used are indicated by abbreviations at the bottom of the figure and are described in Table 3 . ϪIndicates control bacterial extract (BL21(DE3)). Each lane contains 50 fmoles of probe (50 000 cpm) and 1 L of bacterial extract prepared as described in the Methods. Competition at 100-fold excess of competitor was 100% for the AIIAB and SRE-1 probe and up to Ϸ90% to 95% for the other probes. B, DNA binding of SREBP-1 (1-460) to the SRE-1 probe, and competition of binding by unlabeled oligonucleotides corresponding to the regulatory elements SRE-1 of the LDL receptor gene, AIIAB, AIICD, AIIDE, and AIIHI of the apoA-II gene, and CIIIB of the apoC-III gene. DNA binding and competition assays were performed with SREBP-1 (1-460) expressed in bacteria as explained in the Methods. The competitor oligonucleotides were used at 10-to 250-fold molar excess relative to the 32 P labeled SRE-1 probe. The competitors used are indicated by abbreviation in the insert and are described in Table 3 . The y-axis shows the percent of binding compared with the binding without competitor arbitrarily set to 100%. The x-axis shows the fold excess of competitors used.
transfection of COS-1 and transformation of bacterial BL21(DE3) cells. This analysis showed that SREBP-1 mutants were expressed efficiently in COS-1 as well as in bacterial cells and have the expected molecular mass ( Figure  6A through 6C) . The relative location of the site of mutagenesis of SREBP-1 is shown in Figure 6C .
Transient cotransfection assays showed that SREBP-1 mutants carrying substitution of Ile, Gly, or Val for Lys359 decreased the Ϫ911/29 apoA-II promoter activity, reaching 50% decrease at 500 ng of SREBP-1 (1-460) expression plasmid, as compared with 3.5-fold activation observed with the wild-type SREBP-1 (1-460) . On the other hand, a mutant SREBP-1 (1-460) form carrying a substitution of Arg for Lys359 transactivated 2.5-fold the Ϫ911/29 apoA-II promoter ( Figure 7A ). Qualitatively similar results were obtained when the SREBP-1 mutants were used in cotransfection experiments with the Ϫ911/29 AB wild-type K mutant apoA-II promoter. The activity of this promoter was reduced to approximately 50% to 60% by the mutants carrying substitution of Ile, Gly, or Val for Lys359 and was increased 2-fold by substitution of Arg for Lys359 ( Figure 7B ). These SREBP-1 (1-460) mutants were also used in cotransfection with the apoA-II (Ϫ614/29) promoter constructs. This analysis showed that the mutants carrying substitutions of Ile, Val, or Gly for Lys359 are virtually inactive. Only the mutant carrying a substitution of Arg for Lys359 displayed some transactivation ability ( Figure 7C ). It is important to note that, in the context of the wild-type apoA-II (Ϫ911 to 29) promoter, the mutant carrying a substitution of Arg for Lys359 functions much better compared with the truncated apoA-II (Ϫ614 to 29) promoter ( Figure 7A through 7C ). This suggests that interactions of the SREBP-1 mutant carrying a substitution of Arg for Lys359 with the factors that bind to the apoA-II enhancer region are important for transactivation of the Ϫ911/29 apoA-II promoter by SREBP-1. When the enhancer region that contains regulatory elements AII-I to AIIN is deleted, protein-protein interactions between the mutant SREBP-1 and other factors bound to the enhancer are lost. As a result, transactivation by the mutant protein is severely compromised.
The first 90 amino acids of SREBP-1 contain the transcriptional activation domain of the protein, which is highly acidic in character. Amino-terminal deletion mutants of hamster SREBP-1 behave as dominant negative repressors. 7 To explain the repression of the apoA-II promoter activity by mutants defective in the DNA-binding domain of SREBP-1 (1-460), 2 additional SREBP-1 variants were generated. One variant lacks the first 90 amino-terminal residues (SREBP-1 ⌬90). The second variant lacks the first 90 amino-terminal residues and carries an additional substitution of Ile for Lys359 in its DNA-binding domain (SREBP-1 ⌬90K359I). Both mutants showed similar levels of expression to the wild-type SREBP-1 (1-460) ( Figure 6A and 6B) . Cotransfection of the SREBP-1 ⌬90 mutant along with the wild-type apoA-II (Ϫ911 to 29) promoter decreased the promoter activity to 17% of control ( Figure 7D) ; the double mutant with deletion of the amino-terminal activation domain and substitution of Ile for Lys359 in the DNA-binding domain (SREBP-1 ⌬90K359I) was unable to activate or repress the apoA-II promoter activity ( Figure 7D) . In contrast, the SREBP-1 mutant that carries a substitution of Ile for Lys359 and has an intact activation domain (SREBP-1 K359I) caused a dose-dependent decrease in the Ϫ911/ϩ29 apoA-II promoter activity, which reached 20% of the control value at 2 g of SREBP-1 ( Figure 7E) .
Transactivation of the wild-type apoA-II promoter by SREBP-1 (1-460) correlated with the ability of the SREBP-1 mutant proteins expressed in bacteria to bind to the elements AIIAB and SRE-1 in gel EMSAs. Similar amounts of the SREBP-1 mutant proteins were used in these assays (as assessed by immunoblotting of the bacterial extracts; Figure  6B ). This analysis showed that substitution of Ile, Val, or Gly for Lys359 decreased the binding affinity of SREBP-1 mutant proteins for the SRE-1 and AIIAB elements ( Figure 8A and 8C). The most severe effect was observed with the mutant carrying the substitution of Gly for Lys 359, which did not bind to either element AIIAB or SRE-1 ( Figure 8A and 8C) . As shown in Figure 7A through 7C, all these mutants repressed the apoA-II promoter activity. The SREBP-1 mutant carrying the substitution of Arg for Lys359 showed the best relative binding among the mutants, in agreement with the transactivation data of the Figure 7A through 7C.
Similar analysis showed that the SREBP-1 carrying a deletion at the mutant amino-terminal SREBP-1 ⌬90 could bind efficiently to its cognate sites on element AIIAB and SRE-1 ( Figure   8B and 8D) and could repress the apoA-II promoter activity ( Figure 7D ). In contrast, the double mutant (SREBP-1 ⌬90K359I) displayed weak DNA binding ( Figure 8B and 8D ) and had no effect on the apoA-II promoter activity ( Figure 7D and 7E). The findings suggest that repression by the DNA binding-deficient mutants requires the activation domain of SREBP-1. One unexpected observation from the gel EMSAs was that both deletion mutants SREBP-1 ⌬90 and SREBP-1 ⌬90 K359I displayed a slower migration in the polyacrylamide gel than the wild-type protein ( Figure 8B and 8D) . The cause of this anomalous migration is not known. We speculate that this may be the result of a large change in the structure or charge of the protein caused by the deletion of the acidic amino terminal domain.
Discussion
The present in vitro studies show that the wild-type SREBP-1 binds to 5 sites and transactivates strongly the apoA-II in HepG2 cells whereas SREBP-1 mutants defective in their DNA-binding domain repress the apoA-II promoter activity. A potential role of SREBP-1 in apoA-II gene regulation in vivo was not established.
In Vivo Role of SREBP-1 in Transactivation of Cholesterol-Responsible Genes
In vivo studies in hamsters indicated that SREBP-1 decreases under conditions of cholesterol deprivation and indicates that SREBP-1 may be responsible for maintenance of the basal activity of the cholesterol-responsive genes. 32 Furthermore, expression of the SREBP-1a isoform in transgenic mice caused a massive accumulation of triglycerides and cholesterol in the liver, with elevations in many of the enzymes involved in cholesterol and fatty acid synthesis but did not alter levels of apoA-I, apoB, and apoE mRNA. 33 These data are consistent with cotransfection experiments, which showed that SREBP-1 was unable to transactivate the human apoA-I and apoB promoters (V.I. Zannis, unpublished data, 1996). . Gel EMSA and competition assays using wild-type and mutated oligonucleotides AIIAB and AIIK as probes. DNA binding and competition assays were performed with SREBP-1 expressed in bacteria as explained in the Methods. The competitor oligonucleotides were used at 100-fold molar excess relative to the 32 P labeled probe. They are indicated by abbreviations at the top of the Figure and are described in Table 3 . *Indicates nonspecific binding protein present in bacterial extract. Each lane contains 50 fmoles of probe (50 000 cpm) and 1 L of bacterial extract as described in the Methods.
The apoA-II mRNA levels were not examined in these animals. 33 In the present study RNase protection experiments on HepG2 cell cultures grown in lipoprotein-deficient serum or in the presence or absence of cholesterol and 25-OH-cholesterol showed small relative increase in the apoA-II mRNA/ glycerol-3 phosphate dehydrogenase mRNA in cholesteroldepleted cells compared with cholesterol-overloaded cells. However, no difference was observed in the apoA-II mRNA/ ␤-actin mRNA ratio (data not shown). Thus, despite the multiplicity of SREBP-1 sites on the apoA-II promoter and the in vitro data presented below, apoA-II may behave differently from the prototype cholesterol-responsive genes that are regulated by SREBP.
It is possible that the apoA-II protein, which participates in the transport of cholesterol and other lipids throughout the body, is expressed constitutively most of the time. However the present in vitro data can neither exclude nor support the possibility that cholesterol availability may influence moderately the expression of this gene via SREBP-1 to adjust apoA-II levels to different physiological demands.
SREBP-1 Binds to Multiple Sites and Transactivates the Human ApoA-II Promoter Activity in HepG2 Cells
A total of 5 binding sites for SREBP-1 were found in the apoA-II promoter by DNaseI footprinting using SREBP-1 expressed in bacteria. The reason for the presence of 5 binding sites is not clear, but given the strong activity of the apoA-II promoter in HepG2 cells the multiple sites may be needed to enable SREBP-1 to compete effectively with other factors that can occupy the same sites for the activation of the apoA-II promoter. It has been shown that SREBP-1 recognizes palindromic E-box type CANNTG repeats, which can also be recognized by other members of the bHLHZip family of transcription factors. 5 SREBP-1 can also recognize a direct CACCCCAC repeat, exemplified by the SRE-1 element of the human LDL receptor. 1 It was found that an atypical tyrosine residue present in the bHLHZip domain of SREBP-1 contributes to the dual DNA-binding specificity. 5 The human apoA-II promoter contains both types of SREBP-1-binding sites. The AIICD and AIIDE elements contain a direct repeat, and the AIIAB, AIIHI, and AIIK elements contain a palindromic repeat (Table 2) . DNA binding competition assays showed that the SRE-1 element of the LDL receptor promoter and the AIIAB element from the apoA-II promoter have the highest relative affinity among the elements tested. The lower affinity of the other binding sites does not necessarily exclude them from a potential role in the transactivation of the apoA-II promoter. Several lower-affinity binding sites may bring about high-level synergistic activation of a promoter. As discussed below, the E-box binding sites in the apoA-II promoter (AIIAB and AIIK) are also occupied by other E-box binding proteins, 24, 26 and SREBP-1 would have to compete with them for binding to these elements. On the other hand, the lower-affinity direct repeats AIICD and AIIDE are unique binding sites for SREBP. Thus, despite the lower relative affinity, the binding of SREBP-1 to several sites may bring about synergistic transactivation of the apoA-II promoter.
The approximately 3.5-fold increase in promoter activity by SREBP-1 is significant given the strong activity of this promoter in HepG2 cells. Furthermore, truncated promoter segments that lack the enhancer region (AIII to AIIN) and have low activity can be transactivated up to 40-fold with 0.5 g of SREBP-1. Transactivation depends largely on the number of SREBP-1-binding sites. These findings suggest that, in the context of the entire Ϫ911/29 apoA-II promoter, other factors besides SREBP-1 may become limiting and this is the reason that transactivation reaches a plateau at 3.5-fold in the full-length Ϫ911/29 apoA-II promoter.
The SREBP-1-binding site in the apoC-III promoter (CIIIB) overlaps completely with the binding site of CIIIB1/ USF 26,30,34 -38 and partially with the binding site of nuclear receptors. The binding of both transcription factors to this element may be mutually exclusive ( Figure 1E ). In addition, CIIIB element is a weak binding site for SREBP-1 and this may be the reason that cotransfection experiments with SREBP-1 (1-460) did not significantly affect the apoC-III promoter activity (data not shown).
SREBP-1-Binding Sites on Elements AIIAB and AIIK Overlap With Binding Sites of Transcription Factor CIIIB1/USF
Of the 5 binding sites identified, the AIIAB and AIIK are of special interest because they have been shown previously to bind another nuclear factor, designated CIIIB1. 30 Mutations in sites AIIAB or AIIK that prevented the binding of CIIIB1 to these sites decreased the promoter activity in HepG2 cells to approximately 60% and 20% of control, respectively. The binding of SREBP-1 to elements AIIAB and AIIK overlaps completely with the binding site of factor CIIIB1, a heatstable protein of 41 kDa that has been purified to homogeneity. 30 It was shown recently that several properties of CIIIB1 correspond to the properties of USF1/USF2␣ heterodimers, 2 related and previously described bHLHZip transcription factors. 26,34 -38 USF-mediated transcriptional activation involves interactions with TFIID, 35 TFII-I, 39 and TATA box-binding protein-associated factor TAF II 55 40 and requires positive cofactors. 41 The binding site of CIIIB1 on element CIIIB contains an E-box type motif CACCTG on the antisense strand between nucleotides Ϫ71 and Ϫ76. Nucle- Figure 6C . E, Effect of increasing concentration of the full-length SREBP-1 K359I and the truncated SREBP-1 ⌬90K359I mutants on the wild-type apoA-II promoter activity in HepG2 cells. The cotransfection titration experiments were performed with 3 g of the Ϫ911/29 apoA-II promoter construct, 1 g of the CMV ␤-gal plasmid, and increasing concentration 0 to 2 g of the SREBP-1 plasmids. Forty-eight hours after transfections, cells were harvested and the amount of the CAT enzyme was determined as described in the Methods. The mean values (ϮSD) from 3 independent transfections performed in duplicate are presented.
otide substitutions within this sequence abolished the binding of the purified factor. 30 Purified CIIIB1 protein also protects the region Ϫ65 to Ϫ48 of the apoA-II promoter that contains an identical E-box type CACCTG motif on the sense strand between nucleotides Ϫ59 and Ϫ54. 30 CIIIB1 also binds with high affinity to the regulatory elements AIIK and AIIL of the apoA-II gene. 24 Both the in vitro mutagenesis of the CIIIB1/ USF binding sites and cotransfection experiments suggest that CIIIB1/USF is an activator of the apoA-II promoter activity. 24, 26 Although CIIIB1/USF and SREBP-1 occupy identical sites on elements AIIAB and AIIK on the apoA-II promoter, our findings suggest that the mechanism of transactivation of the apoA-II promoter by these factors may be different. In the former case, binding of the CIIIB1/USF to element AIIK is the most important, whereas in the latter case, binding of SREBP-1 to element AIIAB is the most important. A promoter construct containing the element AIIAB and the apoA-II enhancer displayed a 2-fold increase in activity compared with the wild-type apoA-II promoter and was transactivated 2-fold by SREBP-1. It is interesting that although mutation in either element AIIAB or AIIK decreased the activity of this promoter to 50% of the control, transactivation was affected only by mutations in element AIIAB, thus demonstrating the importance of this element for the SREBP-1-mediated transactivation. Collectively, our findings suggest that the SREBP-1-binding sites in the apoA-II promoter are functional and the binding of SREBP-1 to these sites leads to the transactivation of the apoA-II promoter. In contrast, promoters that contain weak SREBP-1-binding sites, such as the apoC-III promoter, or promoters that lack SREBP-1 sites, such as apoA-I, are not transactivated by SREBP-1 (Zannis VI and Nagaoka, unpublished data, 1996).
Mutations in the DNA-Binding and Activation Domains of SREBP-1 Repress ApoA-II Promoter Activity
Previous mutagenesis in the DNA-binding domain of SREBP-1 that targeted an atypical tyrosine residue showed that this amino acid is required for the recognition of the direct repeat motif. 5 The mutations reported in this study targeted the Lys 359 residue, which is located at the beginning of the second helix of the helix-loop-helix domain ( Figure 6D ). An unexpected finding of our early work was that mutation of this residue with substituted Ile for Lys359 not only decreased the binding of SREBP-1 to DNA, but also decreased the apoA-II promoter activity to 20% of control. 31 The crystal structures of other bHLHZip proteins have indicated that the homologous Lys residue is contacting the backbone of the DNA and is making a hydrogen bond with an Asn residue that also contacts the backbone of the DNA. 42 Thus, we rationalized that this Lys residue might contribute to the overall affinity of SREBP-1 for DNA but probably might not alter its binding specificity to direct or palindromic repeats.
Previous studies using SREBP-1 constructs containing mutations in the DNA-binding domain reduced by 31% to 50% the activity of reporter CAT constructs driven by 2 copies of repeats 2 and 3 of the LDL receptor promoter. 7 This homopolymeric promoter has relatively low activity and has to be transactivated by wild-type SREBP-1 to observe repression by SREBP mutants defective in DNA binding. Therefore any negative regulatory effect by SREBP-1 mutants might have been pronounced compared with the apoA-II promoter, which has high activity in HepG2 cells and is more sensitive to inhibitory than stimulatory factors. To understand the underlying reasons for the inhibitory effects of this SREBP-1 mutant, we introduced additional mutations in SREBP-1 by substituting Gly, Val, or Arg for Lys359. Two other mutants were also constructed: 1 that carries deletion of the activation domain (SREBP-1 ⌬90) and another which combined the amino-terminal deletion with the substitution of Ile for Lys359 (SREBP-1 ⌬90K359I). The binding and activation properties of these SREBP-1 mutants were tested by DNA binding as well as in cotransfection experiments. As expected, substitutions of Ile, Gly, or Val for Lys359 significantly decreased the binding of SREBP-1 expressed in bacteria to their cognate sites on the elements AIIAB and SRE-1 compared with the wild-type SREBP-1. The SREBP-1 mutant carrying a substitution of Gly for Lys 359 actually lost completely its ability to bind to the DNA. It is possible that introduction of a glycine residue at position 359 could have a significant impact on the adjacent secondary structures of SREBP-1, because glycine lacks a side chain and has a large rotational freedom. On the other hand, substitution of Arg for Lys359 had only a slight impact on the binding of SREBP-1 to the AIIAB and SRE-1 elements. Most of the members of the bHLHZip family have a conserved Lys residue at this position except Max, which has an Arg residue ( Figure 6D ). 43 Thus conservation of a positive charge at position 359 appears to be necessary for efficient binding of SREBP-1 to DNA. Binding of the other SREBP-1 mutants containing a deletion of their activation domain also yielded some interesting information. Unexpectedly, the deletion mutants exhibited a slower migration in native polyacrylamide gel than their full-length counterparts. Such anomalous migration is usually attributed to a large conformational change of the mutated protein. In the case of SREBP-1, deletion of the amino-terminal domain resulted in the loss of 16 acidic amino acid residues. Thus the deletion mutant 1 to 90 SREBP-1⌬90, which binds as a dimer to DNA, would have 32 fewer negative charges per complex with DNA than the full-length SREBP-1 and this difference could explain at least partially the different mobility of the DNA-protein complex to the cathode. Consistent with this interpretation is the observation that retardation in the migration of mutants carrying deletion of amino acids 1 to 90 (SREBP-1 ⌬90 and SREBP-1 ⌬90 K359I) is more pronounced on the SRE-1 probe, which is 18-bp long, than on the AIIAB probe, which is 36-bp long (Table 3) . Deletion of the activation domain is usually not expected to affect the binding of a transcription factor. In our experiments, the deletion mutant SREBP-1 ⌬90 showed a somewhat weaker binding to the AIIAB element compared with the full-length SREBP-1, but it displayed strong binding to the SRE-1 element. It has been proposed that positioning of the 2 monomers of SREBP-1 is different on palindromic and direct repeat elements (AIIAB and SRE-1, respectively), 4 and their dimerization interface may also be different. This could be responsible for the difference observed in binding of the SREBP-1 mutants carrying a deletion of residues 1 to 90 to the AIIAB and SRE-1 elements.
The activation properties of the SREBP-1 mutants correlate well with their DNA binding in vitro to the elements AIIAB and SRE-1. The SREBP-1 mutants carrying substitutions of Ile, Gly, or Val for Lys359 have lower binding ability and repress the apoA-II promoter. On the other hand, the mutant having substitution of Arg for Lys359, which retains relatively good binding, is still able to transactivate the apoA-II promoter albeit weaker than the wild-type SREBP-1. Binding of SREBP-1 to DNA and the presence of an intact activation domain are essential for SREBP-1 to transactivate the apoA-II promoter. Thus, consistent with previous findings, 7 deletion of the amino-terminal region of SREBP-1, which contains an acidic activation domain, converts the protein from an activator to a repressor. This repression could result from competitive displacement of the positive regulator CIIIB1/USF that binds to the same sites. 30 Another possibility would be recruitment of an active repressor by the activationdefective form of SREBP-1. 44, 45 Insight into the mechanism of this repression was obtained by comparison of the 2 mutants that carry substitution of Ile for Lys359, but only 1 of them has the amino-terminal activation domain deleted (SREBP-1 K359I and SREBP-1 ⌬90K359I). This analysis showed that the full-length mutant with defects in DNA binding repressed the apoA-II promoter activity in a dose-dependent fashion whereas the truncated mutant that lacks the activation domain and is defective in DNA binding did not have any effect. It is possible that the activation domain of the mutant SREBP-1 K359I, which is defective in DNA binding, associates with another factor that is important for the activation of the apoA-II promoter. This association could titrate this putative factor out of the promoter, thus causing a decrease in the apoA-II promoter activity. Similar interference has been observed in other systems as well. 46 The identity of the putative titratable factor remains unknown. However, recent studies have shown that CBP (cyclicAMP regulatory element-binding protein) associates with the activation domain of SREBP-1 and enhances its activation potential. 47 CBP also associates with many transcription factors 46 -51 and possesses histone acetylase activity, which is thought to cause remodeling of the chromatin structure. [52] [53] [54] In summary, this study documents that SREBP-1 binds to multiple sites on 2 types of binding motifs in vitro and transactivates different apoA-II promoter segments in HepG2 cells. SREBP-1 mutants defective in their DNA-binding domain repress the apoA-II promoter activity, possibly by a squelching mechanism. We suggest that apoA-II promoter constructs containing multiple SREBP-1-binding motifs may become valuable probes in future studies to assess different activation domains of SREBP-1 and possibly its interactions with potential coactivators or corepressors. Additional studies are required to establish a potential role of SREBP-1 in apoA-II gene regulation in vivo.
